Global Methotrexate Drugs Market- Drivers
Increasing number of drug approvals by regulatory bodies is expected to drive the global methotrexate drugs market growth over the forecast period.
Increasing number of drug approvals by regulatory bodies is expected to boost the growth of global methotrexate drugs market. For instance, on March 30, 2022, NORDIC PHARMA, a SEVER Life Sciences company, announced the submission of a New Drug Submission to Health Canada for its methotrexate auto-injector, Nordimet for the treatment of severe disabling active rheumatoid arthritis (RA) and symptomatic control of severe, recalcitrant, disabling psoriasis in adults who are not adequately responsive to other forms of therapy.
Furthermore, on September 26, 2022, Eisai Co., Ltd., and nippon medac Co., Ltd., a subsidiary of medac Gesellschaft für klinische Spezialpräparate mbH announced that they have obtained manufacturing and marketing approval from the Japanese Ministry of Health, Labour and Welfare for the indication of the anti-rheumatic agent “Metoject Subcutaneous Injection 7.5mg syringe 0.15mL, 10mg syringe 0.20mL, 12.5mg syringe 0.25mL and 15mg syringe 0.30mL” (methotrexate) for the treatment of rheumatoid arthritis.
Global Methotrexate Drugs Market: Restraints
Side effects associated to Methotrexate drugs, is expected to hinder the growth of global methotrexate drugs market. Side effects associated with methotrexate drugs are:
Restraints
Side effects associated to Methotrexate drugs, is expected to hinder the growth of global methotrexate drugs market. Side effects associated with methotrexate drugs are:
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients